Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03344536 · ClinicalTrials.gov registry record · Phase 1
A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT03344536: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03344536 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03344536, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of a phase Ib study is to find out the best or maximum tolerated dose of a medication or combination of medications. Therefore, the purpose of this study is to decide the best dose of the study drug, Debio 1347, that can be given in combination with the standard hormonal drug, fulvestrant. Debio 1347 and fulvestrant could shrink the cancer but it could also cause side effects. This study tells us about the side effects of these drugs when given in this new combination, and how often they occur.
Interventions
- DRUG Fulvestrant
- DRUG Debio 1347
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-11-10 |
| Est. Completion | 2021-08-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03344536
The ClinicalTrials.gov registry entry for NCT03344536 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fulvestrant is the first listed.
NCT03344536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03344536 about?
NCT03344536 is a clinical study titled "A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer". The purpose of a phase Ib study is to find out the best or maximum tolerated dose of a medication or combination of medications. Therefore, the purpose of this study is to decide the best dose of the study drug, Debio 1347, that can be given in combination with the standard hormonal drug, fulvestran...
What is the current status of trial NCT03344536?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2017-11-10. Estimated completion is 2021-08-12.
What interventions are being tested in trial NCT03344536?
The interventions under investigation include: Fulvestrant (DRUG), Debio 1347 (DRUG).
Who is sponsoring clinical trial NCT03344536?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.